Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

Abstract Background Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in t...

Full description

Bibliographic Details
Main Authors: Sibylle Baechmann, Steffen Ormanns, Michael Haas, Stephan Kruger, Anna Remold, Dominik Paul Modest, Thomas Kirchner, Andreas Jung, Jens Werner, Volker Heinemann, Stefan Boeck
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Pancreatic ductal adenocarcinoma (PDAC)
KRAS mutation
Tumor heterogeneity
Online Access:http://link.springer.com/article/10.1186/s12885-017-3376-4

Internet

http://link.springer.com/article/10.1186/s12885-017-3376-4

Similar Items